Circadin Den Europæiske Union - dansk - EMA (European Medicines Agency)

circadin

rad neurim pharmaceuticals eec sarl - melatonin - søvninitierings- og vedligeholdelsesforstyrrelser - psykoleptika - circadin er indiceret som monoterapi til kortvarig behandling af primær søvnløshed, der er karakteriseret ved dårlig søvnkvalitet hos patienter over 55 år eller derover.

Slenyto Den Europæiske Union - dansk - EMA (European Medicines Agency)

slenyto

rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders; autistic disorder - psykoleptika - slenyto er indiceret til behandling af søvnløshed hos børn og unge i alderen 2-18 med autisme spektrum forstyrrelse (asf) og / eller smith-magenis syndrom, hvor søvn hygiejne foranstaltninger ikke har været tilstrækkelige.

Xenleta Den Europæiske Union - dansk - EMA (European Medicines Agency)

xenleta

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibakterielle midler til systemisk brug, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Melatonin Neurim Den Europæiske Union - dansk - EMA (European Medicines Agency)

melatonin neurim

rad neurim pharmaceuticals eec sarl - melatonin - søvninitierings- og vedligeholdelsesforstyrrelser - psykoleptika - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

Zydelig Den Europæiske Union - dansk - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Xtandi Den Europæiske Union - dansk - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatiske neoplasmer - endokrine terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.